Role of arginine, taurine and homocysteine in cardiovascular diseases

被引:68
作者
Niittynen, L
Nurminen, ML
Korpela, R
Vapaatalo, H
机构
[1] Univ Helsinki, Dept Pharmacol & Toxicol, Inst Biomed, FIN-00014 Helsinki, Finland
[2] Valio Ltd, Res & Dev, Helsinki, Finland
关键词
arginine; cardiovascular disease; homocysteine; taurine;
D O I
10.3109/07853899908995898
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Arginine, taurine and homocysteine are amino acids which have been shown to affect the risk factors of cardiovascular diseases in humans. Arginine and taurine may protect against cardiovascular diseases while homocysteine may be a risk factor for them. Both arginine and taurine seem to lower blood pressure, arginine may also inhibit atherogenesis, and taurine may have antioxidant properties, However, the evidence of the beneficial effects of arginine and taurine supplementation from human studies is insufficient. Elevated levels of plasma homocysteine may be associated with atherosclerotic and thromboembolic cardiovascular diseases. Supplementation with folic acid seems to be effective in reducing hyperhomocysteinaemia, but there is an insufficient number of studies showing that lowering of homocysteine levels with vitamin supplementation will reduce the risk of cardiovascular diseases. In conclusion, further research is needed to determine the optimal levels for taurine and arginine in the human diet in order to decrease the risk factors for cardiovascular diseases, and to whom supplementation with folic acid should possibly be recommended to reduce hyperhomocysteinaemia. Even though the use of arginine and taurine supplements to reduce cardiovascular risk factors is an interesting possibility, the reported health-promoting effects and the safety of such a supplementation should first: be confirmed.
引用
收藏
页码:318 / 326
页数:9
相关论文
共 85 条
[1]
Oral L-arginine improves endothelium-dependent dilatation and reduces monocyte adhesion to endothelial cells in young men with coronary artery disease [J].
Adams, MR ;
McCredie, R ;
Jessup, W ;
Robinson, J ;
Sullivan, D ;
Celermajer, DS .
ATHEROSCLEROSIS, 1997, 129 (02) :261-269
[2]
ORAL L-ARGININE INHIBITS PLATELET-AGGREGATION BUT DOES NOT ENHANCE ENDOTHELIUM-DEPENDENT DILATION IN HEALTHY-YOUNG MEN [J].
ADAMS, MR ;
FORSYTH, CJ ;
JESSUP, W ;
ROBINSON, J ;
CELERMAJER, DS .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1995, 26 (04) :1054-1061
[3]
THE ANTIOXIDANT ACTION OF TAURINE, HYPOTAURINE AND THEIR METABOLIC PRECURSORS [J].
ARUOMA, OI ;
HALLIWELL, B ;
HOEY, BM ;
BUTLER, J .
BIOCHEMICAL JOURNAL, 1988, 256 (01) :251-255
[4]
TAURINE FOR TREATMENT OF CONGESTIVE HEART-FAILURE [J].
AZUMA, J ;
HASEGAWA, H ;
SAWAMURA, A ;
AWATA, N ;
HARADA, H ;
OGURA, K ;
KISHIMOTO, S .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 1982, 2 (02) :303-304
[5]
USEFULNESS OF TAURINE IN CHRONIC CONGESTIVE-HEART-FAILURE AND ITS PROSPECTIVE APPLICATION [J].
AZUMA, J ;
SAWAMURA, A ;
AWATA, N .
JAPANESE CIRCULATION JOURNAL-ENGLISH EDITION, 1992, 56 (01) :95-99
[6]
AZUMA J, 1983, CLIN THER, V5, P398
[7]
OZONE-INDUCED LIPID-PEROXIDATION AND MEMBRANE LEAKAGE IN ISOLATED RAT ALVEOLAR MACROPHAGES - PROTECTIVE EFFECTS OF TAURINE [J].
BANKS, MA ;
PORTER, DW ;
MARTIN, WG ;
CASTRANOVA, V .
JOURNAL OF NUTRITIONAL BIOCHEMISTRY, 1991, 2 (06) :308-313
[8]
BOGER RH, 1995, ATHEROSCLEROSIS, V117, P273, DOI 10.1016/0021-9150(95)05582-H
[9]
Dietary L-arginine reduces the progression of atherosclerosis in cholesterol-fed rabbits - Comparison with lovastatin [J].
Boger, RH ;
BodeBoger, SM ;
Brandes, RP ;
Phivthongngam, L ;
Bohme, M ;
Nafe, R ;
Mugge, A ;
Frolich, JC .
CIRCULATION, 1997, 96 (04) :1282-1290
[10]
A QUANTITATIVE ASSESSMENT OF PLASMA HOMOCYSTEINE AS A RISK FACTOR FOR VASCULAR-DISEASE - PROBABLE BENEFITS OF INCREASING FOLIC-ACID INTAKES [J].
BOUSHEY, CJ ;
BERESFORD, SAA ;
OMENN, GS ;
MOTULSKY, AG .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 274 (13) :1049-1057